Synpromics 12th in the Deloitte UK Technology Fast 50. Synpromics is delighted to announce that it has been ranked 12th in the Deloitte ‘UK Technology Fast 50’ at the annual awards ceremony in London last night.
“Antimicrobial resistance is a real and current threat” – this was the warning we heard from David Roblin of Summit therapeutics in our recent interview for our Celebrating UK bioscience series. Antimicrobial resistance affects every nation on earth, and it’s getting worse. Much like the problem of climate change, the effects have been growing steadily and the problem does not respect boundaries. Infections arising from antimicrobial resistant microbes poses one of the greatest threats to modern medicine.
In response to the announcement that UK Cabinet has approved the draft Brexit deal, BIA CEO, Steve Bates, said: "We welcome this week's progress on Brexit discussions with the initial agreement between the EU and UK on a withdrawal agreement and the political agreement on the outline of a future relationship. The BIA will now monitor and inform its members of the political debate that will ensue in the finely balanced UK parliament. There is significant detail to digest and we are engaging with members and others to understand the implications of the deal for the life sciences sector, and plan to produce a detailed briefing on this next week.
The winner of this year’s Peter Dunnill Award to be presented at the bioProcessUK conference has been announced as Professor Alvin Nienow. Alvin is Emeritus Professor of Biochemical Engineering at the University of Birmingham, a Visiting Professor at Aston and Loughborough Universities and a Fellow of the Royal Academy of Engineering. In addition to this the Advanced Therapies Manufacturing Taskforce has been announced as the winner of the Richard Wilson Impact award.
This week I am in China with a number of BIA members. This trip is the centrepiece of the BIA’s ramp up of engagement East in 2018. Building on our China Special Interest Group we are seeking to increase the number of UK biotech companies collaborating with, generating revenue from, and receiving investment from the Chinese market. In Hong Kong I am exploring how we can jointly build the life science analytical capability needed for global liquidity - and make dual listing - or similar - a practical reality for UK companies seeking investment there.
Medicines Discovery Catapult and the National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs) announce strategic collaboration to accelerate the translation of more predictive in vitro research models into new products and services
Medicines Discovery Catapult and the Medical Research Council (MRC) Centre for Drug Safety Science (CDSS) at the University of Liverpool announce strategic collaboration to develop next generation human cell models